CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with early Alzheimer’s disease

BACKGROUND: Efavirenz is an anti-HIV drug, and cytochrome P450 46A1 (CYP46A1) is a CNS-specific enzyme that metabolizes cholesterol to 24-hydroxycholesterol (24HC). We have previously shown that allosteric CYP46A1 activation by low-dose efavirenz in a transgenic mouse model of Alzheimer’s disease (A...

Descripción completa

Detalles Bibliográficos
Autores principales: Lerner, Alan J., Arnold, Steven E., Maxfield, Erin, Koenig, Aaron, Toth, Maria E., Fortin, Brooke, Mast, Natalia, Trombetta, Bianca A., Denker, John, Pieper, Andrew A., Tatsuoka, Curtis, Raghupathy, Sangeetha, Pikuleva, Irina A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797897/
https://www.ncbi.nlm.nih.gov/pubmed/36581878
http://dx.doi.org/10.1186/s13195-022-01151-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797897/
https://www.ncbi.nlm.nih.gov/pubmed/36581878
http://dx.doi.org/10.1186/s13195-022-01151-z

Ejemplares similares